Tags

Type your tag names separated by a space and hit enter

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients.
Neurol Sci. 2020 Sep; 41(9):2353-2366.NS

Abstract

COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug-drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes.

Authors+Show Affiliations

Pediatric Clinic, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy.Psychiatric Clinic, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy. dott.martinacorsi@gmail.com.Pediatric Clinic, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy.Pediatric Neurology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.Pediatric Clinic, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy.Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.Pediatric Neurology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32767055

Citation

Orsini, Alessandro, et al. "Challenges and Management of Neurological and Psychiatric Manifestations in SARS-CoV-2 (COVID-19) Patients." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 41, no. 9, 2020, pp. 2353-2366.
Orsini A, Corsi M, Santangelo A, et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. Neurol Sci. 2020;41(9):2353-2366.
Orsini, A., Corsi, M., Santangelo, A., Riva, A., Peroni, D., Foiadelli, T., Savasta, S., & Striano, P. (2020). Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(9), 2353-2366. https://doi.org/10.1007/s10072-020-04544-w
Orsini A, et al. Challenges and Management of Neurological and Psychiatric Manifestations in SARS-CoV-2 (COVID-19) Patients. Neurol Sci. 2020;41(9):2353-2366. PubMed PMID: 32767055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. AU - Orsini,Alessandro, AU - Corsi,Martina, AU - Santangelo,Andrea, AU - Riva,Antonella, AU - Peroni,Diego, AU - Foiadelli,Thomas, AU - Savasta,Salvatore, AU - Striano,Pasquale, Y1 - 2020/08/06/ PY - 2020/05/25/received PY - 2020/06/21/accepted PY - 2020/8/9/pubmed PY - 2020/8/18/medline PY - 2020/8/9/entrez KW - Brain KW - CNS KW - COVID-19 KW - Coronavirus KW - Neurologic KW - Psychiatric KW - SARS-CoV-2 SP - 2353 EP - 2366 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 41 IS - 9 N2 - COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug-drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/32767055/Challenges_and_management_of_neurological_and_psychiatric_manifestations_in_SARS_CoV_2__COVID_19__patients_ L2 - https://link.springer.com/10.1007/s10072-020-04544-w DB - PRIME DP - Unbound Medicine ER -